Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
Blood Adv. 2017 Sep 12;1(20):1729-1738
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
Cancer. 2017 Dec 06;:
Expert Opin Pharmacother. 2017 Oct 20;:1-16
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Ann Hematol. 2017 Oct 03;:
Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients.
Clin Microbiol Infect. 2017 Sep 29;:
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.
Am J Hematol. 2017 Oct;92(10):1037-1046
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Lancet Oncol. 2017 Aug 24;:
Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study.
Clin Lymphoma Myeloma Leuk. 2017 Jun 29;:
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Br J Haematol. 2017 Jul 05;: